Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: A randomized phase III trial

Journal of Clinical Oncology

Volumn 26, Issue 26, 2008, Pages 4261-4267

  Hermes, Andreas ^a   Bergman, Bengt ^b   Bremnes, Roy ^b   Ek, Lars ^b   Fluge, Sverre ^b   Sederholm, Christer ^b   Sundstrøm, Stein ^b   Thaning, Lars ^b   Vilsvik, Jan ^b   Aasebø, Ulf ^b   Sörenson, Sverre ^b  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ERYTHROPOIETIN; ETOPOSIDE; IRINOTECAN; LOPERAMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TRANSFUSION; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; JAPANESE; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; COMPARATIVE STUDY; LUNG TUMOR; MIDDLE AGED; SMALL CELL CARCINOMA; SURVIVAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, SMALL CELL; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 52049104938     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.7545     Document Type: Article

References (20)

1. Simon GR, Turrisi A: Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines, 2nd edition. Chest 132:324S-339S, 2007 (suppl 3)
2. Slotman B, Faivre-Finn C, Kramer G, et al: Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357:664-672, 2007
3. Sundstrøm S, Bremnes RM, Kaasa S, et al: Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 20:4665-4672, 2002
4. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002
5. Hanna N, Bunn PA Jr, Langer C, et al: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24:2038-2043, 2006
6. de Jongh CA, Wade JC, Finley RS, et al: Trimethoprim/sulfamethoxazole versus placebo: A double-blind comparison of infection prophylaxis in patients with small cell carcinoma of the lung. J Clin Oncol 1:302-307, 1983
7. Nagatomo A, Watanabe K, Kunikane H, et al: A randomized controlled trial of sulfamethoxazole/trimethoprim plus norfloxacin versus sulfamethox-azole/ trimethoprim alone for the prophylaxis of bacterial infection during chemotherapy for lung cancer. Lung Cancer 19:121-125, 1998
8. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
9. Bergman B, Aaronson NK, Ahmedzai S, et al: The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials - EORTC Study Group on Quality of Life. Eur J Cancer 30A: 635-642, 1994
10. Stephens RJ, Hopwood P, Girling DJ: Defining and analysing symptom palliation in cancer clinical trials: A deceptively difficult exercise. Br J Cancer 79:538-544, 1999
11. Bergman B, Sörenson S: Return to work among patients with small cell lung cancer. Eur J Respir Dis 70:49-53, 1987
12. Lassen U, Kristjansen PE, Østerlind K, et al: Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer: A randomized trial with 5 years follow up. Ann Oncol 7:365-371, 1996
13. Skarlos DV, Samantas E, Kosmidis P, et al: Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. Ann Oncol 5:601-607, 1994
14. Schmittel A, Fischer von Weikersthal L, Sebastian M, et al: A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol 17:663-667, 2006
15. Kinoshita A, Fukuda M, Soda H, et al: Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer. Br J Cancer 94:1267-1271, 2006
16. Pfeiffer P, Sørensen P, Rose C: Is carboplatin and oral etoposide an effective and feasible regimen in patients with small cell lung cancer? Eur J Cancer 31A:64-69, 1995
17. Hirsch FR, Hansen HH, Hansen M, et al: The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: A randomized trial of 288 consecutive patients. J Clin Oncol 5:585-591, 1987
18. Hande K, Messenger M, Wagner J, et al: Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Clin Cancer Res 5:2742-2747, 1999
19. Kroschinsky FP, Friedrichsen K, Mueller J, et al: Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP regimen for malignant lymphomas. Cancer Che-mother Pharmacol 61:785-790, 2008
20. Würthwein G, Krümpelmann S, Tillmann B, et al: Population pharmacokinetic approach to compare oral and i.v. administration of etoposide. Anticancer Drugs 10:807-814, 1999